Altimmune Inc. products

A peptide-based dual GLP-1/glucagon receptor agonist designed to treat the metabolic dysfunction that causes non-alcoholic steatohepatitis (NASH). NASH, the most severe form of non-alcoholic fatty liver disease (NAFLD), involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, leading to fibrosis or eventually liver cancer. Because ALT-801 acts across these multiple pathways, it may be able to correct the metabolic dysfunction at the heart of NASH as demonstrated in one of the best preclinical models of the disease.

An immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). It is designed to drive CD4+ and CD8+ T-cell responses against all HBV genotypes in patients of diverse genetic backgrounds. Normally, the HBV virus is eliminated through T cell dependent mechanisms but stimulating these responses in chronically infected HBV patients has been challenging due to the exhaustion of T cells directed against the virus. HepTcell has shown the potential to  break the immunotolerance characteristic of this disease and activate T cells to fight the infection.